About Bryologyx

About company

BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies. The company is capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development.